Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Pediatric Drugs
Erschienen in: Pediatric Drugs 5/2019

01.10.2019 | Review Article

Drug-Induced Urolithiasis in Pediatric Patients

verfasst von: Maria Chiara Sighinolfi, Ahmed Eissa, Luigi Bevilacqua, Ahmed Zoeir, Silvia Ciarlariello, Elena Morini, Stefano Puliatti, Viviana Durante, Pier Luca Ceccarelli, Salvatore Micali, Giampaolo Bianchi, Bernardo Rocco

Erschienen in: Pediatric Drugs | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Drug-induced nephrolithiasis is a rare condition in children. The involved drugs may be divided into two different categories according to the mechanism involved in calculi formation. The first one includes poorly soluble drugs that favor the crystallization and calculi formation. The second category includes drugs that enhance calculi formation through their metabolic effects. The diagnosis of these specific calculi depends on a detailed medical history, associated comorbidities and the patient’s history of drug consumption. There are several risk factors associated with drug-induced stones, such as high dose of consumed drugs and long duration of treatment. Moreover, there are some specific risk factors, including urinary pH and the amount of fluid consumed by children. There are limited data regarding pediatric lithogenic drugs, and hence, our aim was to perform a comprehensive review of the literature to summarize these drugs and identify the possible mechanisms involved in calculi formation and discuss the management and preventive measures for these calculi.
Literatur
1.
Marra G, Taroni F, Berrettini A, Montanari E, Manzoni G, Montini G. Pediatric nephrolithiasis: a systematic approach from diagnosis to treatment. J Nephrol. 2019;32(2):199–210.PubMedCrossRef
2.
Scoffone CM, Cracco CM. Pediatric calculi: cause, prevention and medical management. Curr Opin Urol. 2018;28(5):428–32.PubMedCrossRef
3.
Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC, Rule AD. Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol. 2012;188(1):247–52.PubMedPubMedCentralCrossRef
4.
Tasian GE, Ross ME, Song L, Sas DJ, Keren R, Denburg MR, et al. Annual incidence of nephrolithiasis among children and adults in South Carolina from 1997 to 2012. Clin J Am Soc Nephrol: CJASN. 2016;11(3):488–96.PubMedCrossRef
5.
Tasian GE, Kabarriti AE, Kalmus A, Furth SL. Kidney stone recurrence among children and adolescents. J Urol. 2017;197(1):246–52.PubMedCrossRef
6.
Routh JC, Graham DA, Nelson CP. Epidemiological trends in pediatric urolithiasis at United States freestanding pediatric hospitals. J Urol. 2010;184(3):1100–4.PubMedCrossRef
7.
Alfandary H, Haskin O, Davidovits M, Pleniceanu O, Leiba A, Dagan A. Increasing prevalence of nephrolithiasis in association with increased body mass index in children: a population based study. The Journal of urology. 2018;199(4):1044–9.PubMedCrossRef
8.
Bowen DK, Tasian GE. Pediatric stone disease. Urol Clin N Am. 2018;45(4):539–50.CrossRef
9.
Bevill M, Kattula A, Cooper CS, Storm DW. The modern metabolic stone evaluation in children. Urology. 2017;101:15–20.PubMedCrossRef
10.
Cameron MA, Sakhaee K, Moe OW. Nephrolithiasis in children. Pediatr Nephrol (Berlin, Germany). 2005;20(11):1587–92.CrossRef
11.
Cambareri GM, Kovacevic L, Bayne AP, Giel D, Corbett S, Schurtz E, et al. National multi-institutional cooperative on urolithiasis in children: age is a significant predictor of urine abnormalities. J Pediatr Urol. 2015;11(4):218–23.PubMedCrossRef
12.
Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs. 2018;78(2):163–201.PubMedCrossRef
13.
14.
Copelovitch L. Urolithiasis in children: medical approach. Pediatr Clin N Am. 2012;59(4):881–96.CrossRef
15.
Albala DM, Prien EL Jr, Galal HA. Urolithiasis as a hazard of sulfonamide therapy. J Endourol. 1994;8(6):401–3.PubMedCrossRef
16.
Catalano-Pons C, Bargy S, Schlecht D, Tabone MD, Deschenes G, Bensman A, et al. Sulfadiazine-induced nephrolithiasis in children. Pediatr Nephrol (Berlin, Germany). 2004;19(8):928–31.CrossRef
17.
Antopol W, Robinson H. Urolithiasis and renal pathology after oral administration of 2(sulfanilylamino)pyridine (sulfapyridine). Proc Soc Exp Biol Med. 1939;40(3):428–30.CrossRef
18.
de Liso F, Garigali G, Ferraris Fusarini C, Daudon M, Fogazzi GB. How to identify sulfamethoxazole crystals in the urine. Clinica chimica acta; Int J Clin Chem. 2016;452:106–8.
19.
Becker K, Jablonowski H, Haussinger D. Sulfadiazine-associated nephrotoxicity in patients with the acquired immunodeficiency syndrome. Medicine. 1996;75(4):185–94.PubMedCrossRef
20.
21.
Erturk E, Casemento JB, Guertin KR, Kende AS. Bilateral acetylsulfapyridine nephrolithiasis associated with chronic sulfasalazine therapy. J Urol. 1994;151(6):1605–6.PubMedCrossRef
22.
23.
Sasson JP, Dratch PL, Shortsleeve MJ. Renal US findings in sulfadiazine-induced crystalluria. Radiology. 1992;185(3):739–40.PubMedCrossRef
24.
Chatchen S, Pongsakul N, Srisomsap C, Chiangjong W, Hongeng S, Svasti J, et al. Unravelling pathophysiology of crystalline nephropathy in ceftriaxone-associated acute kidney injury: a cellular proteomic approach. Nephron. 2018;139(1):70–82.PubMedCrossRef
25.
Schaad UB, Tschappeler H, Lentze MJ. Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy. Pediatr Infect Dis. 1986;5(6):708–10.PubMedCrossRef
26.
Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet (London, England). 1988;2(8625):1411–3.CrossRef
27.
Acun C, Erdem LO, Sogut A, Erdem CZ, Tomac N, Gundogdu S, et al. Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study. Ann Trop Paediatr. 2004;24(1):25–31.PubMedCrossRef
28.
Akl KF, Masri AT, Hjazeen MM. Acute urine retention induced by ceftriaxone. Saudi J Kidney Dis Transplant. 2011;22(6):1226–8.
29.
Kimata T, Kaneko K, Takahashi M, Hirabayashi M, Shimo T, Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis. Pediatric Nephrol (Berlin, Germany). 2012;27(4):605–9.CrossRef
30.
Azarfar A, Esmaeeli M, Ravanshad Y, Bagheri S, Khodashenas E, Ghane-Sharbaf F, et al. Hypercalciuria following ceftriaxone a fact or myth. J Renal Injury Prev. 2015;4(3):101–3.
31.
Youssef DM, Sherief LM, Sherbiny HS, ElAttar MY, Sheikh AR, Fawzy FM, et al. Prospective study of nephrolithiasis occurrence in children receiving cefotriaxone. Nephrology (Carlton, Vic). 2016;21(5):432–7.CrossRef
32.
Lozanovski VJ, Gucev Z, Avramoski VJ, Kirovski I, Makreski P, Tasic V. Ceftriaxone associated urolithiasis in a child with hypercalciuria. Hippokratia. 2011;15(2):181–3.PubMedPubMedCentral
33.
Avci Z, Koktener A, Uras N, Catal F, Karadag A, Tekin O, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child. 2004;89(11):1069–72.PubMedPubMedCentralCrossRef
34.
Li N, Zhou X, Yuan J, Chen G, Jiang H, Zhang W. Ceftriaxone and acute renal failure in children. Pediatrics. 2014;133(4):e917–22.PubMedCrossRef
35.
Shen X, Liu W, Fang X, Jia J, Lin H, Xu M, et al. Acute kidney injury caused by ceftriaxone-induced urolithiasis in children: a single-institutional experience in diagnosis, treatment and follow-up. Int Urol Nephrol. 2014;46(10):1909–14.PubMedCrossRef
36.
Fesharakinia A, Ehsanbakhsh AR, Ghorashadizadeh N. Ceftriaxone-associated nephrolithiasis in children. Iran J Pediatr. 2013;23(6):643–7.PubMedPubMedCentral
37.
Cochat P, Cochat N, Jouvenet M, Floret D, Wright C, Martin X, et al. Ceftriaxone-associated nephrolithiasis. Nephrol Dial Transpl. 1990;5(11):974–6.CrossRef
38.
Ustyol L, Bulut MD, Agengin K, Bala KA, Yavuz A, Bora A, et al. Comparative evaluation of ceftriaxone- and cefotaxime-induced biliary pseudolithiasis or nephrolithiasis: a prospective study in 154 children. Hum Exp Toxicol. 2017;36(6):547–53.PubMedCrossRef
39.
de Moor RA, Egberts AC, Schroder CH. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis. Eur J Pediatr. 1999;158(12):975–7.PubMedCrossRef
40.
Prince JS, Senac MO Jr. Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child. Pediatr Radiol. 2003;33(9):648–51.PubMedCrossRef
41.
Gargollo PC, Barnewolt CE, Diamond DA. Pediatric ceftriaxone nephrolithiasis. J Urol. 2005;173(2):577–8.PubMedCrossRef
42.
Tasic V, Sofijanova A, Avramoski V. Nephrolithiasis in a child with acute pyelonephritis Ceftriaxone-induced nephrolithiasis and biliary pseudolithiasis. Pediatr Nephrol (Berlin, Germany). 2005;20(10):1510–1.CrossRef
43.
Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghojevand N, et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol (Berlin, Germany). 2007;22(5):690–4.CrossRef
44.
Stojanovic V, Djuric Vijatov G. Nephrolithiasis caused by ceftriaxone in a 3-year-old child with ureteropelvic junction obstruction. Case Rep Med. 2009;2009:365962.PubMedPubMedCentralCrossRef
45.
Biner B, Oner N, Celtik C, Bostancioglu M, Tuncbilek N, Guzel A, et al. Ceftriaxone-associated biliary pseudolithiasis in children. J Clin Ultrasound: JCU. 2006;34(5):217–22.PubMedCrossRef
46.
Zhang Y, Ning B, Zhu H, Cong X, Zhou L, Wang Q, et al. Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review. Int Urol Nephrol. 2016;48(7):1061–9.PubMedCrossRef
47.
Cong X, Gu X, Sun X, Ning B, Shen L. Possible function of urinary pH and citrate on the ceftriaxone-induced nephrolithiasis. Urology. 2014;83(1):63–7.PubMedCrossRef
48.
Watson RA, Ettinger B, Deshon GE Jr, Agee RE, Oldroyd NO. Triamterene stone: advantage of crystallographic analysis. Urology. 1981;18(3):238–40.PubMedCrossRef
49.
50.
Ghousheh AI, Groth TW, Fryjoff KM, Wille DF, Mandel NS, Roddy JT, et al. Urolithiasis in patients on high dose felbamate. J Urol. 2013;189(5):1865–9.PubMedCrossRef
51.
Meier KH, Olson KR, Olson JL. Acute felbamate overdose with crystalluria. Clin Toxicol (Phila). 2005;43(3):189–92.CrossRef
52.
Fairbridge RW. SILICA, SILICATESilica, silicate Encyclopedia of planetary science. Dordrecht: Springer; 1997.
53.
Tasdemir M, Fucucuoglu D, Ozman O, Sever L, Onal B, Bilge I. Silicate calculi, a rare cause of kidney stones in children. Pediatr Nephrol (Berlin, Germany). 2017;32(2):371–4.CrossRef
54.
Ulinski T, Sabot JF, Bourlon I, Cochat P. Bilateral urinary calculi after treatment with a silicate-containing milk thickener. Eur J Pediatr. 2004;163(4–5):239–40.PubMedCrossRef
55.
van Rossum AM, Dieleman JP, Fraaij PL, Cransberg K, Hartwig NG, Gyssens IC, et al. Indinavir-associated asymptomatic nephrolithiasis and renal cortex atrophy in two HIV-1 infected children. AIDS (London, England). 2001;15(13):1745–7.CrossRef
56.
Noble CB, Klein LT, Staiman VR, Neu N, Hensle TW, Berdon WE. Ureteral obstruction secondary to indinavir in the pediatric HIV population. Pediatr Radiol. 1998;28(8):627–9.PubMedCrossRef
57.
Tasian GE, Jemielita T, Goldfarb DS, Copelovitch L, Gerber JS, Wu Q, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol: JASN. 2018;29(6):1731–40.PubMedCrossRef
58.
Bohles H, Gebhardt B, Beeg T, Sewell AC, Solem E, Posselt G. Antibiotic treatment-induced tubular dysfunction as a risk factor for renal stone formation in cystic fibrosis. J Pediatr. 2002;140(1):103–9.PubMedCrossRef
59.
Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, et al. Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet (London, England). 1998;352(9133):1026–9.CrossRef
60.
Pacifici GM. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. Paediatr Drugs. 2012;14(4):233–46.PubMedCrossRef
61.
Alpert SA, Noe HN. Furosemide nephrolithiasis causing ureteral obstruction and urinoma in a preterm neonate. Urology. 2004;64(3):589.PubMedCrossRef
62.
Alon US, Scagliotti D, Garola RE. Nephrocalcinosis and nephrolithiasis in infants with congestive heart failure treated with furosemide. J Pediatr. 1994;125(1):149–51.PubMedCrossRef
63.
Ali SK. Renal calculi complicating short-term furosemide therapy after congenital heart surgery. Congenit Heart Dis. 2006;1(5):251–3.PubMedCrossRef
64.
Stafstrom CE, Gilmore HE, Kurtin PS. Nephrocalcinosis complicating medical treatment of posthemorrhagic hydrocephalus. Pediatr Neurol. 1992;8(3):179–82.PubMedCrossRef
65.
Pope JCT, Trusler LA, Klein AM, Walsh WF, Yared A, Brock JW. The natural history of nephrocalcinosis in premature infants treated with loop diuretics. J Urol. 1996;156(2 Pt 2):709–12.PubMedCrossRef
66.
Hufnagle KG, Khan SN, Penn D, Cacciarelli A, Williams P. Renal calcifications: a complication of long-term furosemide therapy in preterm infants. Pediatrics. 1982;70(3):360–3.PubMed
67.
Noe HN, Bryant JF, Roy S 3rd, Stapleton FB. Urolithiasis in pre-term neonates associated with furosemide therapy. J Urol. 1984;132(1):93–4.PubMedCrossRef
68.
Ezzedeen F, Adelman RD, Ahlfors CE. Renal calcification in preterm infants: pathophysiology and long-term sequelae. J Pediatr. 1988;113(3):532–9.PubMedCrossRef
69.
70.
Mohamed GB, Ibrahiem MA, Abdel Hameed WM. Nephrocalcinosis in pre-term neonates: a study of incidence and risk factors. Saudi J Kidney Dis Transpl. 2014;25(2):326–32.PubMedCrossRef
71.
Chang HY, Hsu CH, Tsai JD, Li ST, Hung HY, Kao HA, et al. Renal calcification in very low birth weight infants. Pediatr Neonatol. 2011;52(3):145–9.PubMedCrossRef
72.
Narendra A, White MP, Rolton HA, Alloub ZI, Wilkinson G, McColl JH, et al. Nephrocalcinosis in preterm babies. Arch Dis Child Fetal Neonatal Ed. 2001;85(3):F207–13.PubMedPubMedCentralCrossRef
73.
Blickman JG, Herrin JT, Cleveland RH, Jaramillo D. Coexisting nephrolithiasis and cholelithiasis in premature infants. Pediatr Radiol. 1991;21(5):363–4.PubMedCrossRef
74.
Glasier CM, Stoddard RA, Ackerman NB Jr, McCurdy FA, Null DM Jr, deLemos RA. Nephrolithiasis in infants: association with chronic furosemide therapy. AJR Am J Roentgenol. 1983;140(1):107–8.PubMedCrossRef
75.
Saarela T, Lanning P, Koivisto M, Paavilainen T. Nephrocalcinosis in full-term infants receiving furosemide treatment for congestive heart failure: a study of the incidence and 2-year follow up. Eur J Pediatr. 1999;158(8):668–72.PubMedCrossRef
76.
Gimpel C, Krause A, Franck P, Krueger M, von Schnakenburg C. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. Pediatr Int. 2010;52(1):51–6.PubMedCrossRef
77.
Downing GJ, Egelhoff JC, Daily DK, Alon U. Furosemide-related renal calcifications in the premature infant. A longitudinal ultrasonographic study. Pediatr Radiol. 1991;21(8):563–5.PubMedCrossRef
78.
Hoppe B, Duran I, Martin A, Kribs A, Benz-Bohm G, Michalk DV, et al. Nephrocalcinosis in preterm infants: a single center experience. Pediatr Nephrol (Berlin, Germany). 2002;17(4):264–8.CrossRef
79.
80.
Katayama F, Miura H, Takanashi S. Long-term effectiveness and side effects of acetazolamide as an adjunct to other anticonvulsants in the treatment of refractory epilepsies. Brain Dev. 2002;24(3):150–4.PubMedCrossRef
81.
Carlsen J, Durcan J, Zabriskie N, Swartz M, Crandall A. Nephrolithiasis with dorzolamide. Arch Ophthalmol (Chicago, Ill: 1960). 1999;117(8):1087–8.
82.
Parfitt AM. Acetazolamide and sodium bicarbonate induced nephrocalcinosis and nephrolithiasis; relationship to citrate and calcium excretion. Arch Intern Med. 1969;124(6):736–40.PubMedCrossRef
83.
Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: extent, mechanism and effects. Br J Clin Pharmacol. 2009;68(5):655–61.PubMedPubMedCentralCrossRef
84.
Gupta S, Gao JJ, Emmett M, Fenves AZ. Topiramate and metabolic acidosis: an evolving story. Hosp Pract (1995). 2017;45(5):192–5.PubMedCrossRef
85.
Schwaderer AL, Oduguwa A, Kusumi K. Urinary stone disease in pediatric and adult metabolic bone clinic patients. Urolithiasis. 2018;46(2):173–8.PubMedCrossRef
86.
Ishikawa N, Tani H, Kobayashi Y, Kato A, Kobayashi M. High incidence of renal stones in severely disabled children with epilepsy treated with topiramate. Neuropediatrics. 2019;50(3):160–3.PubMedCrossRef
87.
Goyal M, Grossberg RI, O’Riordan MA, Davis ID. Urolithiasis with topiramate in nonambulatory children and young adults. Pediatr Neurol. 2009;40(4):289–94.PubMedCrossRef
88.
Mahmoud AA, Rizk T, El-Bakri NK, Riaz M, Dannawi S, Al Tannir M. Incidence of kidney stones with topiramate treatment in pediatric patients. Epilepsia. 2011;52(10):1890–3.PubMedCrossRef
89.
Corbin Bush N, Twombley K, Ahn J, Oliveira C, Arnold S, Maalouf NM, et al. Prevalence and spot urine risk factors for renal stones in children taking topiramate. J Pediatr Urol. 2013;9(6 Pt A):884–9.PubMedCrossRef
90.
91.
Yam KM, Yau ML, Fung EL. Nephrolithiasis associated with the use of topiramate in children. Hong Kong Med J = Xianggang yi xue za zhi. 2017;23(6):654–5.
92.
Barnett SM, Jackson AH, Rosen BA, Garb JL, Braden GL. Nephrolithiasis and nephrocalcinosis from topiramate therapy in children with epilepsy. Kidney Int Rep. 2018;3(3):684–90.PubMedPubMedCentralCrossRef
93.
Puri V, Ness S, Sattaluri SJ, Wang S, Todd M, Yuen E, et al. Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. J Child Neurol. 2011;26(10):1271–83.PubMedCrossRef
94.
Dell’Orto VG, Belotti EA, Goeggel-Simonetti B, Simonetti GD, Ramelli GP, Bianchetti MG, et al. Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. Br J Clin Pharmacol. 2014;77(6):958–64.PubMedCrossRef
95.
Kubota M, Nishi-Nagase M, Sakakihara Y, Noma S, Nakamoto M, Kawaguchi H, et al. Zonisamide-induced urinary lithiasis in patients with intractable epilepsy. Brain Dev. 2000;22(4):230–3.PubMedCrossRef
96.
Go T. Effect of antiepileptic drug monotherapy on crystalluria in children and young adults. J Neurol. 2003;250(10):1251–2.PubMedCrossRef
97.
Go T. Effect of antiepileptic drug polytherapy on crystalluria. Pediatr Neurol. 2005;32(2):113–5.PubMedCrossRef
98.
99.
Miyamoto A, Sugai R, Okamoto T, Shirai M, Oki J. Urine stone formation during treatment with zonisamide. Brain Dev. 2000;22(7):460.PubMedCrossRef
100.
Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23(8):1765–73.PubMedCrossRef
101.
Paul E, Conant KD, Dunne IE, Pfeifer HH, Lyczkowski DA, Linshaw MA, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res. 2010;90(1–2):151–6.PubMedPubMedCentralCrossRef
102.
Sampath A, Kossoff EH, Furth SL, Pyzik PL, Vining EP. Kidney stones and the ketogenic diet: risk factors and prevention. J Child Neurol. 2007;22(4):375–8.PubMedCrossRef
103.
Choi JN, Song JE, Shin JI, Kim HD, Kim MJ, Lee JS. Renal stone associated with the ketogenic diet in a 5-year old girl with intractable epilepsy. Yonsei Med J. 2010;51(3):457–9.PubMedPubMedCentralCrossRef
104.
Kossoff EH, Pyzik PL, Furth SL, Hladky HD, Freeman JM, Vining EP. Kidney stones, carbonic anhydrase inhibitors, and the ketogenic diet. Epilepsia. 2002;43(10):1168–71.PubMedCrossRef
105.
Berry-Kravis E, Booth G, Taylor A, Valentino LA. Bruising and the ketogenic diet: evidence for diet-induced changes in platelet function. Ann Neurol. 2001;49(1):98–103.PubMedCrossRef
106.
Shiozawa Y, Sakaguchi S, Sakakibara O, Yagishita K, Saito M, Yamashiro Y. Urolithiasis in an acute lymphoblastic leukemia child during induction chemotherapy. Pediatr Hematol Oncol. 2008;25(4):359–63.PubMedCrossRef
107.
Shields LBE, Peppas DS, Rosenberg E. Xanthine calculi in a patient with Lesch-Nyhan syndrome and factor V Leiden treated with allopurinol: case report. BMC Pediatr. 2018;18(1):231.PubMedPubMedCentralCrossRef
108.
Pais VM Jr, Lowe G, Lallas CD, Preminger GM, Assimos DG. Xanthine urolithiasis. Urology. 2006;67(5):1084.e9–11.CrossRef
109.
Sikora P, Pijanowska M, Majewski M, Bienias B, Borzecka H, Zajczkowska M. Acute renal failure due to bilateral xanthine urolithiasis in a boy with Lesch-Nyhan syndrome. Pediatr Nephrol (Berlin, Germany). 2006;21(7):1045–7.CrossRef
110.
LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol (Berlin, Germany). 2007;22(1):132–5.CrossRef
111.
Landgrebe AR, Nyhan WL, Coleman M. Urinary-tract stones resulting from the excretion of oxypurinol. N Engl J Med. 1975;292(12):626–7.PubMedCrossRef
112.
Greene ML, Fujimoto WY, Seegmiller JE. Urinary xanthine stones–a rare complications of allopurinol therapy. N Engl J Med. 1969;280(8):426–7.PubMedCrossRef
113.
Brock WA, Golden J, Kaplan GW. Xanthine calculi in the Lesch-Nyhan syndrome. J Urol. 1983;130(1):157–9.PubMedCrossRef
114.
Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabol Clin Exp. 2007;56(9):1179–86.PubMedCrossRef
115.
Potter JL, Silvidi AA. Xanthine lithiasis, nephrocalcinosis, and renal failure in a leukemia patient treated with allopurinol. Clin Chem. 1987;33(12):2314–6.PubMed
116.
Howard SC, Kaplan SD, Razzouk BI, Rivera GK, Sandlund JT, Ribeiro RC, et al. Urolithiasis in pediatric patients with acute lymphoblastic leukemia. Leukemia. 2003;17(3):541–6.PubMedCrossRef
117.
Chen X, Shen L, Gu X, Dai X, Zhang L, Xu Y, et al. High-dose supplementation with vitamin C–induced pediatric urolithiasis: the first case report in a child and literature review. Urology. 2014;84(4):922–4.PubMedCrossRef
118.
Conti G, Chirico V, Lacquaniti A, Silipigni L, Fede C, Vitale A, et al. Vitamin D intoxication in two brothers: be careful with dietary supplements. J Pediatr Endocrinol Metabol JPEM. 2014;27(7–8):763–7.
119.
Pozzi M, Locatelli F, Galbiati S, Beretta E, Carnovale C, Clementi E, et al. Relationships between enteral nutrition facts and urinary stones in a cohort of pediatric patients in rehabilitation from severe acquired brain injury. Clin Nutr (Edinburgh, Scotland). 2019;38(3):1240–5.CrossRef
120.
Barata CB, Valete COS. Clinical-epidemiological profile of 106 pediatric patients with urolithiasis in Rio De Janeiro, Brazil. Revista paulista de pediatria: orgao oficial da Sociedade de Pediatria de Sao Paulo. 2018;36(3):261–7.
121.
Hoffmeister PA, Storer BE, Baker KS, Hingorani SR. Nephrolithiasis in pediatric hematopoietic cell transplantation with up to 40 years of follow-up. Pediatr Blood Cancer. 2014;61(3):417–23.PubMedCrossRef
122.
Cranefield DJ, Odd DE, Harding JE, Teele RL. High incidence of nephrocalcinosis in extremely preterm infants treated with dexamethasone. Pediatr Radiol. 2004;34(2):138–42.PubMedCrossRef
Metadaten
Titel
Drug-Induced Urolithiasis in Pediatric Patients
verfasst von
Maria Chiara Sighinolfi
Ahmed Eissa
Luigi Bevilacqua
Ahmed Zoeir
Silvia Ciarlariello
Elena Morini
Stefano Puliatti
Viviana Durante
Pier Luca Ceccarelli
Salvatore Micali
Giampaolo Bianchi
Bernardo Rocco
Publikationsdatum
01.10.2019
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 5/2019
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-019-00355-5

Weitere Artikel der Ausgabe 5/2019

Pediatric Drugs 5/2019 Zur Ausgabe

Original Research Article

Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis

Review Article

Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children

Original Research Article

Oral Lorazepam is not Superior to Placebo for Lowering Stress in Children Before Digestive Endoscopy: A Double-Blind, Randomized, Controlled Trial

Adis Drug Evaluation

DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination

Review Article

Bullous Diseases in Children: A Review of Clinical Features and Treatment Options

Commentary

Good Pharmacovigilance Practice in Paediatrics: An Overview of the Updated European Medicines Agency Guidelines

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise